Cytosorbents Corporation (NASDAQ:CTSO) has been given a $13.00 target price by research analysts at HC Wainwright in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s target price suggests a potential upside of 179.57% from the company’s previous close.
A number of other research firms have also weighed in on CTSO. Maxim Group set a $10.00 target price on Cytosorbents Corporation and gave the company a “buy” rating in a report on Monday, July 17th. B. Riley reaffirmed a “buy” rating and set a $11.25 target price on shares of Cytosorbents Corporation in a report on Wednesday, May 10th. Finally, Aegis reaffirmed a “buy” rating and set a $9.00 target price on shares of Cytosorbents Corporation in a report on Tuesday, May 9th. Six analysts have rated the stock with a buy rating, Cytosorbents Corporation presently has a consensus rating of “Buy” and an average price target of $12.71.
Shares of Cytosorbents Corporation (NASDAQ CTSO) opened at 4.65 on Tuesday. The firm’s 50-day moving average is $4.71 and its 200-day moving average is $4.86. Cytosorbents Corporation has a 52 week low of $3.30 and a 52 week high of $6.90. The firm’s market capitalization is $130.70 million.
Cytosorbents Corporation (NASDAQ:CTSO) last posted its earnings results on Monday, August 7th. The medical research company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.02. The business had revenue of $3.57 million during the quarter, compared to analyst estimates of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. Equities analysts anticipate that Cytosorbents Corporation will post ($0.27) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/08/10/cytosorbents-corporation-ctso-pt-set-at-13-00-by-hc-wainwright.html.
In other Cytosorbents Corporation news, insider Phillip P. Chan acquired 6,300 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was bought at an average price of $4.00 per share, with a total value of $25,200.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have bought 17,500 shares of company stock valued at $70,620 in the last three months. 5.60% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Segantii Capital Management Ltd raised its position in shares of Cytosorbents Corporation by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock valued at $122,000 after buying an additional 23,100 shares during the last quarter. Cowen Group Inc. acquired a new position in shares of Cytosorbents Corporation during the first quarter valued at approximately $248,000. Sabby Management LLC acquired a new position in shares of Cytosorbents Corporation during the first quarter valued at approximately $990,000. Finally, Skylands Capital LLC raised its position in shares of Cytosorbents Corporation by 1,276.5% in the first quarter. Skylands Capital LLC now owns 316,600 shares of the medical research company’s stock valued at $1,425,000 after buying an additional 293,600 shares during the last quarter. 9.74% of the stock is owned by institutional investors.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.